- GW Pharmaceuticals (NASDAQ:GWPH -7.5%) FQ4 results (₤): Revenues: 7.4M (+4.2%); R&D Expense: 12.3M (+33.7%); G&A: 1.8M (+125.0%); Operating Loss: (1.7M) (+50.0%); Net Income: 0.3M (+111.1%); EPS: 0.1p (+106.7%).
- FY2014 results (₤): Revenues: 30M (+9.9%); R&D Expense: 43.5M (+33.0%); G&A: 7.3M (+102.8%); Operating Loss: (19.6M) (-86.7%); Net Loss: (14.7M) (-226.7%); Loss Per Share: (7.0p) (-133.3%); Quick Assets: 164.5M (+331.8%); CF Ops: (12.6M) (-68.0%).
- No guidance given.